Kazia in pact with Dana-Farber for its lead asset in primary CNS lymphoma

Kazia Therapeutics (KZIA +0.9%) has collaborated with Dana-Farber Cancer Institute (DFCI), to investigate its lead drug, paxalisib (formerly GDC-0084), in primary central nervous system (PCNSL) lymphoma, a potential new indication for the drug.

DFCI will initiate an open-label Phase 2 trial of paxalisib in PCNSL, and expects to recruit up to 25 patients, taking up to 2 years to complete. This trial will be sixth ongoing trial of paxalisib in brain cancer.

Kazia will provide support including study drug and a financial grant.

https://seekingalpha.com/news/3616195-kazia-inks-clinical-pact-dana-farber-cancer-institute-for-lead-asset-in-primary-cns-lymphoma